Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clinical cancer research Marabelle, A., Kohrt, H., Levy, R. 2013; 19 (19): 5261-5263


Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.

View details for DOI 10.1158/1078-0432.CCR-13-1923

View details for PubMedID 23965900

View details for PubMedCentralID PMC3817012